Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Pathalys Pharma has raised $105.0M in total funding. The most recent round was Series B. The last funding was announced in August 2024.
Pathalys Pharma's investors include J.P. Morgan Asset Management, The Carlyle Group, Samsara BioCapital, TCG Crossover, Abingworth.
Pathalys Pharma is headquartered in Raleigh, United States.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease.
Pathalys Pharma is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pathalys Pharma — Funding & Investors." VCBacked, August 20, 2024, https://www.vcbacked.co/company/pathalys-pharma. Accessed July 31, 2026.
VCBacked. (2024). Pathalys Pharma — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/pathalys-pharma
{{cite web |title=Pathalys Pharma — Funding & Investors |url=https://www.vcbacked.co/company/pathalys-pharma |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated